Literature DB >> 28736371

[Multifocal electroretinography for therapeutic effect evaluation of intravitreal injection Lucentis for wet age-related macular degeneration].

Rui-Hong Ju1, Man-Sha He, Jin-Tong Hou, Meng-Yuan Li, Jing-Lin Zhang, Zhe-Ming Wu.   

Abstract

OBJECTIVE: To evaluate the changes in retinal functions using multifocal electroretinography (mfERG) following intravitreal injection of Lucentis for treatment of wet age-related macular degeneration.
METHODS: This prospective study was conducted in 14 patients (9 men and 5 women, 14 eyes) with wet age-related macular degeneration receiving treatment with intravitreal injections of ranibizumab (Lucentis) in our hospital between October, 2014 and January, 2016. All the patients received the treatment following a 1+PRN protocol and after the initial injection, the patients were followed up monthly for 6 months to decide if additional injections were needed. The corrected visual acuity and mfERG findings of the patients were assessed before and at l, 3 and 6 months after the initial injection.
RESULTS: At the last follow-up, the patients received injections for a mean of 2.86∓1.58 times. The best corrected visual acuity (BCVA) at 1 month after the initial treatment was not significantly different from that before treatment (P=0.07), but showed significant improvements at 3 and 6 months (P<0.05). In mfERG, the implicit time of the 6 rings showed no significant decrease after the treatment, but the amplitude density of P1 and N1 in rings 1 and 2 improved significantly at 1, 3, and 6 months after the initial injection (P<0.05).
CONCLUSION: Multifocal electroretinography can serve as a useful modality for evaluating visual function changes in patients receiving intravitreal injection of Lucentis for wet age-related macular degeneration.

Entities:  

Year:  2017        PMID: 28736371      PMCID: PMC6765510     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  26 in total

1.  Five-year incidence, progression, and risk factors for age-related macular degeneration: the age, gene/environment susceptibility study.

Authors:  Fridbert Jonasson; Diana E Fisher; Gudny Eiriksdottir; Sigurdur Sigurdsson; Ronald Klein; Lenore J Launer; Tamara Harris; Vilmundur Gudnason; Mary Frances Cotch
Journal:  Ophthalmology       Date:  2014-04-24       Impact factor: 12.079

2.  Evaluation of treatment efficacy of intravitreal ranibizumab injections in patients with wet type of AMD.

Authors:  Wojciech Lubiński; Katarzyna Mozolewska-Piotrowska; Kamila Krasodomska; Krzysztof Penkala; Beata Kaźmierczak; Danuta Karczewicz
Journal:  Klin Oczna       Date:  2012

3.  Multifocal electroretinography in subjects with age-related macular degeneration.

Authors:  Güliz Fatma Yavas; Tuncay Küsbeci; Umit Ubeyt Inan
Journal:  Doc Ophthalmol       Date:  2014-09-25       Impact factor: 2.379

4.  Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.

Authors:  Pasi Vottonen; Eila Kankaanpää
Journal:  Acta Ophthalmol       Date:  2016-08-02       Impact factor: 3.761

5.  Ranibizumab in the treatment of choroidal neovascularisation due to age-related macular degeneration: an optical coherence tomography and multifocal electroretinography study.

Authors:  Marilita M Moschos; Dimitrios Brouzas; Irini P Chatziralli; Ioannis Ladas
Journal:  Clin Exp Optom       Date:  2011-03-09       Impact factor: 2.742

6.  Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels.

Authors:  Zsolt Ablonczy; Mohammad Dahrouj; Alexander G Marneros
Journal:  FASEB J       Date:  2014-02-20       Impact factor: 5.191

7.  The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK.

Authors:  Wrik Ghosh; Rose Wickstead; Lindsay Claxton; Jeanette Kusel; Matthew Taylor; Kelly Fleetwood; Ruth Pulikottil-Jacob
Journal:  Adv Ther       Date:  2016-07-25       Impact factor: 3.845

8.  The role of the ERG in the diagnosis and treatment of Age-Related Macular Degeneration.

Authors:  Christina Gerth
Journal:  Doc Ophthalmol       Date:  2008-06-07       Impact factor: 2.379

9.  Five-year incidence of age-related macular degeneration: the Beijing Eye Study.

Authors:  Qi Sheng You; Liang Xu; Hua Yang; Yi Bin Li; Shuang Wang; Jin Da Wang; Jing Shang Zhang; Ya Xing Wang; Jost B Jonas
Journal:  Ophthalmology       Date:  2012-08-24       Impact factor: 12.079

10.  Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.

Authors:  Robert L Avery; Alessandro A Castellarin; Nathan C Steinle; Dilsher S Dhoot; Dante Joseph Pieramici; Robert See; Stephen Couvillion; Ma'an A Nasir; Melvin D Rabena; Kha Le; Mauricio Maia; Jennifer E Visich
Journal:  Br J Ophthalmol       Date:  2014-07-07       Impact factor: 4.638

View more
  1 in total

1.  Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration.

Authors:  Marion Schroeder; Ulrika Kjellström; Monica Lövestam-Adrian
Journal:  Doc Ophthalmol       Date:  2022-02-26       Impact factor: 1.854

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.